Product Datasheet

CDX2 Antibody - BSA Free
NB100-2136

Unit Size: 100 ul

Store at 4C. Do not freeze.

www.novusbio.com technical@novusbio.com

Reviews: 1 Publications: 12

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NB100-2136

Updated 2/21/2025 v.20.1



NB100-2136

CDX2 Antibody - BSA Free

Product Information	
Unit Size	100 ul
Concentration	1.0 mg/ml
Storage	Store at 4C. Do not freeze.
Clonality	Polyclonal
Preservative	0.09% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	Tris-Citrate/Phosphate (pH 7.0 - 8.0)

Product Description	
Host	Rabbit
Gene ID	1045
Gene Symbol	CDX2
Species	Human, Mouse
Reactivity Notes	Mouse reactivity reported in scientific literature (PMID:33207226).
Immunogen	The immunogen recognized by this antibody maps to a region between residue 250 and 300 of human Caudal Type Homeobox Transcription Factor 2 using the numbering given in entry NP_001256.1 (GeneID 1045).

Product Application Details	
Applications	Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot (Negative)
Recommended Dilutions	Immunohistochemistry 1:500-1:2000, Immunoprecipitation 1-4 ug/mg lysate, Immunohistochemistry-Paraffin 1:500 - 1:2000, Western Blot (Negative)
Application Notes	Western Blot Not recommended. Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections.

Images

Immunohistochemistry-Paraffin: CDX2 Antibody [NB100-2136] - FFPE section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-CDX2 used at a dilution of 1:1,000 (1ug/ml). Detection: DAB	
Immunoprecipitation: CDX2 Antibody [NB100-2136] - Detection of Human CDX2 on HeLa whole cell lysate using NB100-2136. CDX2 was also immunoprecipitated by rabbit anti-CDX2 antibody NB100-2137 using 3 mcg/mg lysate.	

Publications

Mena-Osuna R, Mantrana A, Guil-Luna S et al. Metabolic shift underlies tumor progression and immune evasion in S-nitrosoglutathione reductase-deficient cancer The Journal of pathology 2023-04-05 [PMID: 37017456] (IHC, Human)

Mochizuki K, Kudo SE, Kato K et al. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer PloS one 2022-10-20 [PMID: 36264865] (IF/IHC, Human)

Adhikari D, Lee IW, Al-Zubaidi U et al. Depletion of oocyte dynamin-related protein 1 shows maternal-effect abnormalities in embryonic development Science advances 2022-06-17 [PMID: 35704569] (ICC/IF, Mouse)

Kasashima H, Duran A, Martinez-OrdoNez A et al. Stromal SOX2 Upregulation Promotes Tumorigenesis through the Generation of a SFRP1/2-Expressing Cancer-Associated Fibroblast Population Dev Cell 2020-11-10 [PMID: 33207226] (IF/IHC, Mouse)

Li Y, Yao Q, Zhang L et al. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer Oncologist 2020-09-14 [PMID: 32926498] (MiAr, Human)

Yao Y, Xu X, Yang L et al. Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer Cell Stem Cell 2019-11-19 [PMID: 31761724] (IF/IHC, Human)

Sandberg TP, Sweere I, van Pelt GW et al. Prognostic value of low CDX2 expression in colorectal cancers with a high stromal content - a short report Cell Oncol (Dordr) 2019-03-08 [PMID: 30847807] (IF/IHC, Human)

Trinh A, Trumpi K, de Sousa E Melo F et al. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry. Clin Cancer Res 2016-07-26 [PMID: 27459899]

Kerschner JL, Harris A. Transcriptional networks driving enhancer function in the CFTR gene. Biochem J 2012-09-01 [PMID: 22671145]

Verzi MP, Shin H, Ho LL et al. Essential and redundant functions of caudal family proteins in activating adult intestinal genes. Mol Cell Biol 2011-05-01 [PMID: 21402776]

Verzi MP, Hatzis P, Sulahian R et al. TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions. Proc Natl Acad Sci U S A 2010-08-01 [PMID: 20696899]

De Sousa E Melo F, Wang X, Jansen M et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013-05-01 [PMID: 23584090] (IHC-P, Human)

Novus Biologicals USA
10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada
21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd
19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information
www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NB100-2136

NBL1-09065	CDX2 Overexpression Lysate
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NB100-2136

Earn gift cards/discounts by submitting a publication using this product: www.novusbio.com/publications